Clinical Trial Update: A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease [Phase 1]

View source ↗

Summary

Clinical trial update outlining a Phase 1 study of Adrixetinib (Q702) in adults with active chronic graft-versus-host disease, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Adrixetinib (Q702) (Adrixetinib)

Snippet

Sponsor: Qurient Co., Ltd. | Conditions: Chronic Graft-Versus-Host Disease | Phase 1 | Status: RECRUITING